Moorer v. Stemgenex Medical Group, Inc.

CourtDistrict Court, S.D. California
DecidedJanuary 8, 2021
Docket3:16-cv-02816
StatusUnknown

This text of Moorer v. Stemgenex Medical Group, Inc. (Moorer v. Stemgenex Medical Group, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Moorer v. Stemgenex Medical Group, Inc., (S.D. Cal. 2021).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 SELENA MOORER, individually and on Case No.: 16-cv-02816-AJB-NLS behalf of others similarly situated, 12 Plaintiffs, ORDER GRANTING PLAINTIFFS’ 13 UNOPPOSED MOTION FOR v. PRELIMINARY APPROVAL OF 14 STEMGENEX MEDICAL GROUP, PARTIAL CLASS ACTION 15 INC., a California corporation; SETTLEMENT STEMGENEX, INC., a California 16 corporation; STEM CELL RESEARCH (Doc. No. 171) 17 CENTRE, INC., a California Corporation; ANDRE P. LALLANDE, D.O., an 18 Individual; SCOTT SESSIONS, M.D., an 19 Individual; RITA ALEXANDER, an Individual; and DOES 1-100, 20 Defendants. 21 22 Presently before the Court is Selena Moorer, Rebecca King, Jennifer Brewer, and 23 Alexandra Gardner, including Subclass A Representatives Jennifer Brewer and Alexandra 24 Gardner, and Subclass B Representatives Andrea Andrews and Jennifer Delaney’s 25 (collectively, “Plaintiffs”) motion for orders: (1) granting preliminary approval of a partial 26 settlement between the Class Members and Defendant Andre P. Lallande, D.O. 27 (“Lallande”) pursuant to Fed. R. Civ. P. 23(e), and (2) finding the settlement between the 28 Class Members and Lallande a “good faith settlement,” within the meaning of Sections 877 1 and 877.6 of the California Code of Civil Procedure. (Doc. No. 171.) The motion is 2 unopposed. Having reviewed the parties’ moving papers under controlling legal authority, 3 and pursuant to Local Civil Rule 7.1.d.1, the Court finds the matter suitable for disposition 4 on the papers and without oral argument. For the reasons set forth below, the Court 5 GRANTS Plaintiffs’ unopposed motion in its entirety. 6 I. BACKGROUND 7 On August 22, 2014, Plaintiffs filed a putative class action complaint against 8 multiple Defendants in the Superior Court of California, County of San Diego, alleging 9 violations of California’s Unfair Competition Law, Business and Professions Code 10 § 17200, et seq., (“UCL”), California’s False Advertising Law, Business and Professions 11 Code § 17500, et seq., (“FAL”), California’s Consumer Legal Remedies Act, California 12 Civil Code § 1770, et seq., (“CLRA”), California’s Health and Safety Code § 24170, et 13 seq., (“Human Experimentation”), 18 U.S.C. § 1961, et seq., (“RICO”), Fraud, Negligent 14 Misrepresentation, and Unjust Enrichment. (Doc. No. 1-2.) On September 15, 2016, 15 Plaintiffs filed a First Amended Complaint, (“FAC”), to include a claim for damages under 16 the CLRA. (Doc. No. 1-3.) The FAC contained similar factual allegations, but added 17 Plaintiff Stephen Ginsberg to the action and alleged an additional claim for Financial Elder 18 Abuse. (Id.) On November 16, 2016, Defendants removed the action to this Court pursuant 19 to 28 U.S.C. § 1441(a) and (b). (Doc. No. 1.) 20 The operative complaint alleges that Defendants engaged in a nationwide scheme to 21 “wrongfully market and sell ‘stem cell treatments’” to consumers who are often “sick or 22 disabled, suffering from incurable diseases and a dearth of hope.” (Doc. No. 24 at 3.) 23 Specifically, Plaintiffs allege that Defendants advertised their “stem cell treatments” to 24 consumers via their website and made misrepresentations that the treatments “effectively 25 treat a multitude of diseases,” when in actuality, Defendants maintained “no reasonable 26 basis” to make these claims. (Id.) Plaintiffs further allege that Defendants represented to 27 consumers that “100% of its prior consumers are satisfied with its service,” while omitting 28 material information about its services, including consumer dissatisfaction and complaints 1 regarding the ineffectiveness of the treatments. (Id.) These statements were based upon 2 “Patient Satisfaction Ratings” or “PSR” collected by Defendants. Plaintiffs represent a 3 class of all consumers nationwide who purchased Stem Cell Treatments from Defendant 4 StemGenex between December 8, 2013 and present, and a subclass of all members of the 5 nationwide class aged 65 years or older at the time of purchase. (Id. ¶¶ 64–65.) Plaintiffs 6 allege that each customer was exposed to Defendants’ website, relied on Defendants’ “false 7 and misleading marketing” of the Stem Cell Treatments, and have been harmed as a result. 8 (Id.) 9 Specifically, Plaintiff Moorer, suffering from lupus, and Plaintiff Gardener, 10 suffering from diabetes, each relied upon the customer satisfaction statistics posted on the 11 StemGenex website in deciding to purchase Defendants’ Stem Cell Treatments. (Id. ¶¶ 8– 12 9A.) Plaintiffs allege that each Plaintiff paid a total of $14,900.00 for the treatment, did not 13 benefit from the treatment, and informed Defendants of their dissatisfaction. (Id. ¶¶ 8–9A, 14 11.) Further, Plaintiffs allege they would “not have paid for the Stem Cell Treatment had 15 they known that the statistics on the StemGenex website regarding consumer satisfaction 16 were false, and that StemGenex had no reasonable basis for its marketing claim that the 17 Stem Cell Treatments were effective to treat diseases as advertised.” (Id. ¶ 10.) 18 II. PROCEDURAL HISTORY 19 On August 6, 2018, Plaintiffs filed a motion for class certification. (Doc. No. 95.) 20 The motion was granted by the Court on June 25, 2019. (Doc. No. 134.) On December 24, 21 2019, the Ninth Circuit issued an order granting a request for permission to appeal this 22 Court’s class certification order by four of the Defendants: StemGenex, Inc., StemGenex 23 Medical Group, Inc., Stem Cell Research Centre, Inc., and Rita Alexander (collectively, 24 “the StemGenex Defendants”). Defendant Lallande filed a motion to join or intervene in 25 the appeal as an appellant. On October 30, 2020, during the pendency of the appeal, 26 Plaintiffs filed an unopposed motion for preliminary approval of partial settlement as to 27 Defendant Lallande only. As a condition of settlement, Defendant Lallande agreed to file 28 a notice of withdrawal of and/or motion to withdraw motion to intervene on October 15, 1 2020, which was granted by the Ninth Circuit on October 30, 2020. (Doc. No. 171-1 at 11.) 2 The appeal as to the StemGenex Defendants is currently pending, and this order follows. 3 III. LEGAL STANDARD 4 “Voluntary conciliation and settlement are the preferred means of dispute resolution 5 in complex class action litigation.” Smith v. CRST Van Expedited, Inc., No. 10-CV-1116- 6 IEG (WMC), 2013 WL 163293, at *2 (S.D. Cal. Jan. 14, 2013) (citing Officers for Justice 7 v. Civil Serv. Comm’n of City & Cnty. of S.F., 688 F.2d 615, 625 (9th Cir. 1982)). “In a 8 class action, however, any settlement must be approved by the court to ensure that class 9 counsel and the named plaintiffs do not place their own interests above those of the absent 10 class members.” Dennis v. Kellogg Co., 697 F.3d 858, 861 (9th Cir. 2012); see also Fed. 11 R. Civ. P. 23(e) (“The claims, issues, or defenses of a certified class may be settled . . . 12 only with the court’s approval.”). 13 IV. DISCUSSION 14 “[C]ourt approval of a class action settlement involves a two-step process— 15 preliminary approval, followed by final approval of the settlement. . . .” In re M.L. Stern 16 Overtime Litig., No. 07-CV-0118-BTM (JMA), 2009 WL 995864, at *3 (S.D. Cal. Apr. 17 13, 2009). In this case, the Court is at the first step—preliminary approval.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
Harry Dennis v. Stephanie Berg
697 F.3d 858 (Ninth Circuit, 2012)
Tech-Bilt, Inc. v. Woodward-Clyde & Associates
698 P.2d 159 (California Supreme Court, 1985)
GACKSTETTER v. Frawley
38 Cal. Rptr. 3d 333 (California Court of Appeal, 2006)
Sherri B. Simpson v. Trump University, LLC
881 F.3d 1111 (Ninth Circuit, 2018)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
In re Wireless Facilities, Inc. Securities Litigation II
253 F.R.D. 607 (S.D. California, 2008)
Bellinghausen v. Tractor Supply Co.
303 F.R.D. 611 (N.D. California, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Moorer v. Stemgenex Medical Group, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/moorer-v-stemgenex-medical-group-inc-casd-2021.